Analyst Price Targets — TRVI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 19, 2025 12:50 pm | — | Stifel Nicolaus | $18.00 | $12.19 | TheFly | Trevi Therapeutics price target raised to $18 from $15 at Stifel |
| November 19, 2025 10:23 am | Roanna Ruiz | Leerink Partners | $16.00 | $11.31 | StreetInsider | Trevi Therapeutics (TRVI) PT Raised to $16 at Leerink Partners |
| November 14, 2025 1:19 pm | Judah Frommer | Morgan Stanley | $19.00 | $11.68 | TheFly | Trevi Therapeutics price target raised to $19 from $18 at Morgan Stanley |
| November 14, 2025 11:51 am | Leland Gershall | Oppenheimer | $24.00 | $11.80 | StreetInsider | Trevi Therapeutics (TRVI) PT Raised to $24 at Oppenheimer |
| October 22, 2024 6:59 am | Oren Livnat | H.C. Wainwright | $6.00 | $3.35 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Trevi Therapeutics (TRVI) |
| October 4, 2024 12:48 pm | Mayank Mamtani | B.Riley Financial | $6.00 | $3.02 | StreetInsider | B.Riley Reiterates Buy Rating on Trevi Therapeutics (TRVI) |
| July 9, 2022 3:59 pm | Leland Gershall | Oppenheimer | $12.00 | $3.95 | Pulse 2.0 | Trevi Therapeutics (TRVI) Stock: $12 Target And Outperform Rating |
Latest News for TRVI
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the pricing of its…
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that it has commenced…
SG Americas Securities LLC raised its stake in Trevi Therapeutics, Inc. (NASDAQ: TRVI) by 93.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 124,562 shares of the company's stock after acquiring an additional 60,017 shares during the quarter. SG Americas
NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management…
Trevi Therapeutics, Inc. (NASDAQ: TRVI - Get Free Report) has earned an average recommendation of "Buy" from the twelve ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and two have assigned a strong buy rating to the company.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TRVI.
U.S. House Trading
No House trades found for TRVI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.